Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
Clinical Trial Initiated in First-Line Treatment of Patients with Head and Neck Cancer
31-Aug-2010 -
Idera Pharmaceuticals, Inc. announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA. The milestone was achieved upon Merck KGaA’s initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 ...
cisplatin
clinical trials
colorectal cancer
+3